Abstract: Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample such as a whole blood sample with one or more leukocidal reagents that reduce or eliminate the metabolic activity of leukocytes, and performing an immunoassay on the amended sample to determine the concentration of analyte in the sample. Preferably, the sample is amended with one or more enzymes and optionally one or more enzyme substrates and cofactors.
Type:
Grant
Filed:
March 30, 2015
Date of Patent:
April 19, 2016
Assignee:
Abbott Point of Care, Inc.
Inventors:
John Lewis Emerson Campbell, Graham Davis, John Emegbero Omakor, Adam Roger Moss, Ganesh Guhados
Abstract: An object of the present invention is to detect a human CXCL1 protein with high sensitivity. An immunoassay method is provided for a human CXCL1 protein, by which human CXCL1 or a fragment thereof in a sample is measured using two or more types of anti-human CXCL1 monoclonal antibodies or fragments thereof, wherein: each of the two or more types of anti-human CXCL1 monoclonal antibodies or fragments thereof specifically recognizes any one of sequence regions of the amino acid sequences shown in SEQ ID NOS: 1-3, which are partial sequences of the amino acid sequence composing a human CXCL1 protein; and the two or more types of anti-human CXCL1 monoclonal antibodies or fragments thereof specifically recognize sequence regions that differ from each other. Monoclonal antibodies or fragments thereof are provided, each of which specifically recognizes any one sequence region of the amino acid sequences shown in SEQ ID NOS: 1-3 and has a new amino acid sequence.
Abstract: The present invention provides methods for assessing complement activation and methods for assessing the ability of an agent or condition of interest to modulate complement activation. The present invention provides methods for assessing whether a subject has or is at increased risk of developing a complement-mediated disorder, e.g., age-related macular degeneration (AMD). Also provided are kits containing materials useful for performing the methods.
Type:
Grant
Filed:
May 21, 2010
Date of Patent:
March 22, 2016
Assignee:
Apellis Pharmaceuticals, Inc.
Inventors:
Zhouning Zhang, Cedric Francois, Pascal Deschatelets, Paul Olson
Abstract: The present invention generally provides methods and systems for performing in vivo flow cytometry by using blood vessels as flow chambers through which flowing cells can be monitored in a live subject in vivo without the need for withdrawing a blood sample. In some embodiments, one or more blood vessels are illuminated with radiation so as to cause a multi-photon excitation of an exogenous fluorophore that was previously introduced into the subject to label one or more cell types of interest. In some other embodiments, rather than utilizing an exogenous fluorophore, endogenous (intrinsic) cellular fluorescence can be employed for in vivo flow cytometry. The emission of fluorescence radiation from such fluorophores in response to the excitation can be detected and analyzed to obtain information regarding a cell type of interest.
Type:
Grant
Filed:
September 30, 2013
Date of Patent:
March 22, 2016
Assignee:
The General Hospital Corporation
Inventors:
Charles P. Lin, Alicia L. Carlson, Clemens Alt, David P. Biss, Costas M. Pitsillides, Chungiang Li
Abstract: A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains DNA (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample.
Abstract: The developed reagent is three-color immunophenotyping reagent for measurement of CD4 positive lymphocytes in peripheral blood. The reagent contains 7-aminoactinomycin D (7-AAD) which intercalates into double stranded DNA and is easily excited at 488 nm. The fluorescence emission of 7-AAD has peak at 670 nm that can be detected with FL3 detector of flow cytometer. The 7-AAD, therefore, stains white blood cells and discriminates it from red blood cells. The reagent also contains fluorescein isothiocyanate (FITC) labeled CD4 monoclonal antibody and phycoerythrin (PE) labeled CD14 monoclonal antibody which are detected with FL1 and FL2 detectors of flow cytometer, respectively. The developed reagent can be used to measure number of CD4 positive lymphocytes in lymphocyte population and monitor monocyte contamination simultaneously. This reagent therefore provides more accuracy results of CD4 positive lymphocyte enumeration.
Type:
Grant
Filed:
June 16, 2003
Date of Patent:
March 15, 2016
Assignees:
National Science and Technology Development Agency, The Thailand Research Fund
Abstract: The invention relates to a method for diagnosing a disease state mediated by pathogenic cells. The method comprises the steps of combining with an ex vivo patient sample a composition comprising a conjugate or complex of the general formula Ab-X wherein the group Ab comprises a ligand that binds to the pathogenic cells and the group X comprises an imaging agent, and detecting the pathogenic cells that express a receptor for the ligand using flow cytometry.
Type:
Grant
Filed:
February 24, 2014
Date of Patent:
March 8, 2016
Assignee:
Purdue Research Foundation
Inventors:
Philip Stewart Low, Wei He, Sumith A. Kularatne
Abstract: The present invention, provides a flow cytometry apparatus for the detection of particles from a plurality of samples comprising: means for moving a plurality of samples comprising particles from a plurality of respective source wells into a fluid flow stream; means for introducing a separation gas between each of the plurality of samples in the fluid flow stream; and means for selectively analyzing each of the plurality of samples for the particles. The present invention also provides a flow cytometry method employing such an apparatus.
Type:
Grant
Filed:
December 19, 2013
Date of Patent:
February 23, 2016
Assignee:
STC.UNM
Inventors:
Larry A. Sklar, Bruce Edwards, Frederick Kuckuck
Abstract: An isolated antibody having a specific binding affinity for a polypeptide comprising the amino acid sequence HTEGKP (SEQ ID NO: 2) phosphorylated at threonine is described. The antibody may be used as biomarker for mitotic cells. A method for using the antibody includes contacting a cell with the antibody and detecting antibody bound to the cell as an indicator of the cell being in the mitotic state. A reagent kit comprising the antibody is also described.
Type:
Grant
Filed:
July 14, 2014
Date of Patent:
February 16, 2016
Assignee:
Florida State University Research Foundation, Inc.
Abstract: The present invention is based on the discovery that hexosamine, and in particular the dynamic O-GlcNAcylation of proteins (modification of proteins by the sugar N-acetylglucosamine) both causes insulin-resistance (a hallmark of type II diabetes) and is responsible for glucose toxicity in the disease. Accordingly, the invention provides methods of diagnosing a subject as having or at risk of having pre-diabetes or diabetes. Also provided are methods of characterizing hyperglycemia in a subject, methods of identifying a protein as being associated with hyperglycemia, and kits for detecting pre-diabetes or diabetes.
Type:
Grant
Filed:
October 31, 2007
Date of Patent:
February 2, 2016
Assignee:
The Johns Hopkins University
Inventors:
Gerald W. Hart, Kyoungsook Park, Christopher D. Saudek, Zihao Wang
Abstract: The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for methods of removing antibodies specific for denatured HLA antigens or antibodies specific for native HLA antigens from a serum sample. In addition, the invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ.
Abstract: Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
Abstract: This application relates to a newly identified animal cell structure, the midbody scar. This structure is a remnant of the midbody that is retained by one daughter cell following cytokinesis and persists through multiple subsequent cell cycles. The midbody scar can be useful as a marker of dividing cells or of a cell's replicative age.
Abstract: Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided.
Abstract: The invention relates to antibody characteristics used to design a whole blood Point of Care Thyroid Stimulating Hormone (TSH) immunoassay using an ELISA sandwich assay lacking one or more wash steps between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).
Type:
Grant
Filed:
November 29, 2011
Date of Patent:
December 1, 2015
Assignee:
Abbott Point of Care Inc.
Inventors:
Dan Wang, Gordon Bruce Collier, Joseph P. Skinner, Qiaoqiao Ruan, Sergey Y. Tetin
Abstract: The invention relates to low wash Thyroid Stimulating Hormone (TSH) immunoassays using an ELISA sandwich assay having limited or no wash step between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).
Type:
Grant
Filed:
November 29, 2011
Date of Patent:
December 1, 2015
Assignee:
Abbott Point of Care Inc.
Inventors:
Dan Wang, Gordon Bruce Collier, Joseph P. Skinner, Qiaoqiao Ruan, Sergey Y. Tetin
Abstract: The present invention concerns a monoclonal antibody and corresponding hybridoma cells and antigens suitable for isolating fetal cells from maternal blood. The inventive monoclonal antibody reacts with a surface antigen present on fetal red blood cells including their nucleated precursor cells, but not with surface antigens on adult erythroid cell.
Type:
Grant
Filed:
September 16, 2013
Date of Patent:
November 24, 2015
Assignee:
KellBenx Inc.
Inventors:
Christiane Hollmann, Silke Zimmermann, Stefan Stachelhaus, Winfried Albert
Abstract: Provided is a method and a kit for testing the immune status of patients with chronic inflammatory diseases by measuring the TCR zeta chain (CD247) expression levels, and in particular a method and a kit for testing the selective downregulation of TCR zeta chain expression in T cells, NK cells, or NKT cells of such patients. Zeta chain expression is measured using antibodies directed against the intracellular zeta chain region, and these levels are compared with the expression levels of other T cell receptor subunits and NK cell markers. Thus, a kit for diagnosis, prognosis, and monitoring the immune status, of patients with chronic inflammatory diseases is presented herein.
Type:
Grant
Filed:
April 7, 2009
Date of Patent:
November 17, 2015
Assignee:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD.
Abstract: Detection of the presence or absence of, RH positive cells in a mixed population with Rh negative cells, as is found in a fetal maternal hemorrhage (FMH). The novel methods utilize gravitational forces or applying magnetic forces to reactive magnetic particles to isolate, distinguish and quantify cells. Particles aggregate and are pulled or settle by gravity through a transparent separating solution into a measuring zone where the volume of Rh positive cells can be measured. Rh positive cell volume is correlated to the volume of the original blood sample as an indication of the number of doses of RhIG needed to be administered to the mother to prevent subsequent Rh immunization.
Type:
Grant
Filed:
February 21, 2012
Date of Patent:
November 10, 2015
Assignee:
Chrome Red Technologies, LLC
Inventors:
Henry A. Graham, John G. Gorman, James P. Rowell